[Our ref.: PS/SC/B397/AUD3/pp February 2, 2018 100F Street NE Washington DC Dear Sirs, We have read Item 4.0l (a) of Biostar Pharmaceuticals, Inc's Form 8-K, which discusses the resignation of Mazars CPA Limited as its independent registered public accounting firm, and we agree with the statements ma]
[______________ FORM 8-K ______________ CURRENT REPORT Date of Report (Date of earliest event reported): December 28, 2017 ______________ BIOSTAR PHARMACEUTICALS, INC. ______________ Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identificati]
[______________ FORM 8-K ______________ CURRENT REPORT Date of Report (Date of earliest event reported): December 28, 2017 ______________ BIOSTAR PHARMACEUTICALS, INC. ______________ Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identificati]
[BY EMAIL ONLY Flat A, 20/F Yun Kai Building 466-472 Nathan Road Kowloon Hong Kong gcas@netvigator.com 12 December 2017 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang City, Shaanxi Province People's Republic of China 712046 wrhaoxing@vip.163.com Attn: The board of directors Dear Sir/M]
[BY EMAIL ONLY Flat A, 20/F Yun Kai Building 466-472 Nathan Road Kowloon Hong Kong gcas@netvigator.com 12 December 2017 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang City, Shaanxi Province People's Republic of China 712046 wrhaoxing@vip.163.com Attn: The board of directors Dear Sir/M]
[Biostar Regains Compliance with NASDAQ Continued Listing Requirement XIANYANG, China, December 4, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced t]
[Biostar Regains Compliance with NASDAQ Continued Listing Requirement XIANYANG, China, December 4, 2017 /PRNewswire/ - Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced t]
[FORM 10-Q (Mark One) ☒ September 30, 2017 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Nu]
[FORM 10-Q (Mark One) ☒ September 30, 2017 For the quarterly period ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Nu]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: September 30, 2017 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained h]
